Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 31 for “"AstraZeneca"”.
-
Estimación de densidades de probabilidades neutrales al riesgo a partir de cadenas de opciones sobre AstraZeneca
… opciones financieras europeas de la empresa AstraZeneca, una de las empresas farmacéuticas que desarrolló una vacuna contra la COVID-19. El uso de las DNR estimadas en torno a episodios de noticias financieras por la fabricación de las vacunas, interrupciones en la fabricación o el suministro …
-
Tailored Base Surge Policy for Middle Echelon in Biologics Supply Chain
The Biologics division of AstraZeneca is a growing part of the business, by introducing new and existing products to more markets and therapy areas. Given uncertainty in both supply and demand, the current strategy includes holding inventory at strategic locations throughout the supply chain to …
-
The Anticompetitive Misuse of Intellectual Property Rights in the European Pharmaceutical Sector
… showcased by a case study of the General Court’s AstraZeneca judgment. The analysis shows that the General Court was correct to dismiss AstraZeneca’s claim that its conduct would not have led to antitrust scrutiny following the US Walker Process Doctrine, which in fact covers similar conduct. …
-
An analysis and mitigation of demand variability on external supply chains
… for new products. In the past six years, AstraZeneca has outperformed its peers in research and development productivity, increasing the number and speed of product launches. The resulting demand variability and shifting operational environment have led to financial and non-financial …
-
Triazole-linked reduced amide isosteres: An approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors and NH-assisted Fürst-Plattner opening of cyclohexene oxides
… described within this work. In February of 2009 AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. concomitantly announced that AstraZeneca licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. The lead compound, PRC200, was discovered …
-
Can Medicare afford to pay for oral chemotherapy drugs? : an evaluation of the problem and introduction of a model to estimate cost
… cover all oral cancer drugs. Gefitinib (Iressa; AstraZeneca) is one of the most interesting of the cohort of novel, targeted oral cancer drugs. Already approved in Japan, it is currently under review by the U.S. FDA. This drug has relatively modest efficacy and few side effects; but it is likely …
-
Inventory modeling for active pharmaceutical ingredient supply chains
… pharmaceutical ingredient (API) supply chains at AstraZeneca (AZ). We assess the inventory levels recommended by a base stock policy with deterministic purchase order lead times at each contracted stage of the supply chains. The single-echelon calculations reveal that safety stock levels are not …
-
Resilient by Design: A Supply Chain Digitalization Journey
… tool designed to enhance the resilience of AstraZeneca’s supply chain, employing a design thinking approach. The tool leverages simulation and business intelligence, providing a versatile platform for conducting stress tests and evaluating response mechanisms across a spectrum of scenarios. …
-
Synthesis of Novel Amino Acids and Peptidomimetics as Tools for Drug Discovery
… a collaboration with Dr. Craig Harris at the AstraZeneca Research Centre (Reims, France). The knowledge of Dr. Harris in the field of Mitsunobu alkylation allowed the development of an original strategy for the preparation of racemic amino acids by direct alkylation of an achiral glycine …
-
Optimizing the Supply Chain Design for Sourcing and Supply of Critical Materials
… impacting sites and products globally across the AstraZeneca (AZ) network. Supply to patients continued; however, a team was created to then manage the supply of critical materials. These materials are typically single sourced and used commonly across multiple AZ sites and brands signifying that a …
-
The Role of Neuroinflammation in Alzheimer's Disease
… amyloid beta 42 antibody from MedImmune (now AstraZeneca). Most neuroinflammation studies have focused extensively on synthetic aggregates and to a much lesser extent on endogenous soluble aggregates from human tissue. The aggregates present in humans are still poorly characterised due to a …
-
Control of selectivity in palladium-catalysed cross-coupling reactions using a sulfonated phosphine ligand
… fluid chromatography in collaboration with AstraZeneca, and later by chemical resolution using a chiral auxiliary, work described in this thesis. The second half of this thesis evaluates the efficacy of this new chiral ligand in two classes of asymmetric Suzuki-Miyaura coupling: …
-
How Museums Engage Visitors’ Self-Efficacy
… and uses this data to characterize the AstraZeneca Human Edge exhibits at the Ontario Science Centre. This study also explores why certain exhibits elicit engagement, and tries to identify if those exhibits and features that cause low inquiry self-efficacy visitors to engage are …
-
The Development and Assessment of Computational Approaches to the Thermodynamics and Kinetics of Binding
… in the receptor. This project was supported by AstraZeneca, and it included an industrial placement in the Structural and Biophysical Sciences area, where the experimental data was generated to characterise the thermodynamics and kinetics of binding of a range of ligands to two biological …
-
Protein and Peptide Solubility - In Silico and In Vitro Approaches
… is that it was carried out in collaboration with AstraZeneca. The effects of pH on the solubility of proteins are well understood at least in outline, but there are no sequence-based methods that can reliably predict the solubility of biologics at varying pH values. Similarly, no prediction method …
-
Machine-assisted synthesis and development in pharmaceutical industry
… with solvent selection tools developed by AstraZeneca and Syngenta. Next, considering all continuous and discrete variables in the reaction, a holistic modelling of Buchwald-Hartwig amine synthesis using DFT-based parameterisation techniques and a dozen machine learning algorithms led to …
-
Investigation of the factors contributing to the physical stability of biological therapeutics
… NMR was developed in collaboration with AstraZeneca. It was then used to investigate whether water content can alter the physical stability of a therapeutic peptide, however, results were somewhat inconclusive. Lastly, a method of producing GLP-1 by recombinant means was adapted to allow …
-
Xenopus laevis as a chemical genetic screening tool for drug discovery and development.
… towards drug development, in collaboration with AstraZeneca we designed a renal function toxicity assay. Renal toxicity is a serious concern in the pharmaceutical industry, being responsible for 7% of preclinical compound dropouts. I developed a biochemical assay in which renal function would be …
-
Development and Characterisation of a Vessel-On-a-Chip Model of Inflammation and Inflammatory Haemostasis
… during a secondment at the funding body, AstraZeneca. Several small molecule inhibitors were tested and siRNA-mediated knockdown of endothelial gene expression was optimised. Modification of the model for different disease indications was also explored, including incorporation of …
-
Improved In Silico Methods for Target Deconvolution in Phenotypic Screens
… applied to aid with the target deconvolution of AstraZeneca phenotypic readouts, in particular for the rationalization of cytotoxicity and cytostaticity in the High-Throughput Screening (HTS) collection. Results from this work highlighted which targets are frequently linked to the cytotoxicity …
Page 1 of 2